Home / Roche gets priority review from FDA for Hemlibra

Roche gets priority review from FDA for Hemlibra

ZURICH (Reuters) – Roche has been given fast-track review by the U.S. Food and Drug Administration (FDA) for its Hemlibra treatment for people with a form of haemophilia, the Swiss drugmaker said on Tuesday.

FILE PHOTO: Swiss drugmaker Roche’s logo is seen at their headquarters in Basel, Switzerland January 28, 2016. REUTERS/Arnd Wiegmann/File Photo

The Basel company said the FDA has granted priority review for the drug for children and adults with hemophilia A without factor VIII inhibitors, with a decision on approval expected on October 4, 2018.

Hemlibra had already received breakthrough therapy designation for the medicine to be used in people who have not yet developed resistance to conventional treatments, called inhibitors, Roche said in April.

About admin

Check Also

Koreas tag-team for wrestling recognition

Image copyright AFP/Getty Image caption The sport dates back to the fourth century and has ...

Leave a Reply

Your email address will not be published. Required fields are marked *